Iclusig is utilized to treat adults with the accompanying leukaemia types who are no longer benefiting by treatment with different medications, or have a specific hereditary distinction known as a T315I mutation:
- constant myeloid leukaemia (CML): a blood cancer including an excessive number of unusual white blood cells in the blood and the bone marrow (where platelets are shaped).
- Philadelphia-chromosome positive acute lymphoblastic leukaemia (Ph+ ALL): a kind of leukaemia including such a large number of youthful white platelets in the blood and blood-forming bone marrow.
- In this sort of leukaemia, a portion of the DNA (hereditary material) has progressed toward becoming improved to shape an abnormal chromosome, the Philadelphia chromosome.
- Iclusig has a place with a gathering of medicines called tyrosine kinase inhibitors. In patients with CML and Ph+ ALL, adjustments in the DNA trigger a signal that advises the body to deliver strange white blood cells. Iclusig blocks this signal, thereby stopping the creation of these cells.
- Iclusig (ponatinib) is a kinase inhibitor demonstrated for the: Treatment of grown-up patients with endless stage, quickened stage, or impact stage endless myeloid leukaemia (CML) or Ph+ ALL for whom no other tyrosine kinase inhibitor (TKI) treatment is shown. “Tablet Iclusig is shown for the treatment of Chronic myeloid leukaemia, Chronic myeloid leukaemia, intense lymphoblastic leukaemia and different conditions.
- Tired feeling
- Muscle or joint pain
- Increased blood pressure
- Pain in your arms, hands, legs, or feet
This is not an exhaustive list of side effects and others may occur. Please contact your doctor immediately if any of these symptoms are found.